Research ExplorerPublicationsThe EBMT activity survey report 2017: a focus on allogeneic ...

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Standard

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. / Passweg, Jakob R; Baldomero, Helen; Basak, Grzegorz W; Chabannon, Christian; Corbacioglu, Selim; Duarte, Rafael; Kuball, Jürgen; Lankester, Arjan; Montoto, Silvia; de Latour, Régis Peffault; Snowden, John A; Styczynski, Jan; Yakoub-Agha, Ibrahim; Arat, Mutlu; Mohty, Mohamad; Kröger, Nicolaus; European Society for Blood and Marrow Transplantation (EBMT).

In: BONE MARROW TRANSPL, Vol. 54, No. 10, 10.2019, p. 1575-1585.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Passweg, JR, Baldomero, H, Basak, GW, Chabannon, C, Corbacioglu, S, Duarte, R, Kuball, J, Lankester, A, Montoto, S, de Latour, RP, Snowden, JA, Styczynski, J, Yakoub-Agha, I, Arat, M, Mohty, M, Kröger, N & European Society for Blood and Marrow Transplantation (EBMT) 2019, 'The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies', BONE MARROW TRANSPL, vol. 54, no. 10, pp. 1575-1585. https://doi.org/10.1038/s41409-019-0465-9

APA

Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., de Latour, R. P., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Arat, M., Mohty, M., Kröger, N., & European Society for Blood and Marrow Transplantation (EBMT) (2019). The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. BONE MARROW TRANSPL, 54(10), 1575-1585. https://doi.org/10.1038/s41409-019-0465-9

Vancouver

Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. BONE MARROW TRANSPL. 2019 Oct;54(10):1575-1585. https://doi.org/10.1038/s41409-019-0465-9

Bibtex

@article{957ad431711f4aa3be567c663da4604c,
title = "The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies",
abstract = "Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.",
keywords = "Journal Article",
author = "Passweg, {Jakob R} and Helen Baldomero and Basak, {Grzegorz W} and Christian Chabannon and Selim Corbacioglu and Rafael Duarte and J{\"u}rgen Kuball and Arjan Lankester and Silvia Montoto and {de Latour}, {R{\'e}gis Peffault} and Snowden, {John A} and Jan Styczynski and Ibrahim Yakoub-Agha and Mutlu Arat and Mohamad Mohty and Nicolaus Kr{\"o}ger and {European Society for Blood and Marrow Transplantation (EBMT)}",
year = "2019",
month = oct,
doi = "10.1038/s41409-019-0465-9",
language = "English",
volume = "54",
pages = "1575--1585",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

AU - Passweg, Jakob R

AU - Baldomero, Helen

AU - Basak, Grzegorz W

AU - Chabannon, Christian

AU - Corbacioglu, Selim

AU - Duarte, Rafael

AU - Kuball, Jürgen

AU - Lankester, Arjan

AU - Montoto, Silvia

AU - de Latour, Régis Peffault

AU - Snowden, John A

AU - Styczynski, Jan

AU - Yakoub-Agha, Ibrahim

AU - Arat, Mutlu

AU - Mohty, Mohamad

AU - Kröger, Nicolaus

AU - European Society for Blood and Marrow Transplantation (EBMT)

PY - 2019/10

Y1 - 2019/10

N2 - Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.

AB - Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.

KW - Journal Article

U2 - 10.1038/s41409-019-0465-9

DO - 10.1038/s41409-019-0465-9

M3 - SCORING: Journal article

C2 - 30728439

VL - 54

SP - 1575

EP - 1585

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 10

ER -